CEACAM5 and colorectal carcinoma: reported that the low concentration (0.1–1 ng/mL) of MEDI-565 (also known as AMG 211), developed from the mentioned constructs, could engage patients’ T cells to kill CEA-positive CRC specimens derived from patients that previously received conventional chemotherapy.